USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
AERIS THERAPEUTICS, INC.
Address:
AERIS THERAPEUTICS, INC.
10K GILL ST
WOBURN, MA 01801 0172
Phone:
(781) 937-0110
URL:
N/A
EIN:
43531052
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $195,000.00 2
SBIR Phase II $855,484.00 1

Award List:

Pneumedoreductive Surfacant - New Therapy for Emphysema

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$95,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This Phase I SBIR application is presented by Bistech, Inc. of Woburn, MA. It will test the feasibility of using a new inhaled pharmaceutical agent, pneumoreductive surfactant (PRS), to treat pulmonary emphysema, a progressive and disabling disease that affects… More

Enzymatic Pleurodesis for Malignant Pleural Effusions

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This Phase I SBIR application is presented by Aeris Therapeutics, Inc. of Woburn, MA. It will examine the feasibility of using a novel enzyme based-system to produce safe, clinically-effective pleurodesis for treatment of malignant pleural effusions.… More

Pneumoreductive Surfactant Therapy for Emphysema

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$855,484.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Aeris therapeutics is developing a novel medical treatment for patients with advanced emphysema known as Pneumoreductive Surfactant (PRS). PRSs are inhaled drugs that increase lung recoil by safely altering the surface tension properties of native lung… More